|
Bio-Kinetic Clinical Applications
is a drug development services company that designs and conducts
Phase I clinical studies for branded pharmaceutical, biotechnology,
and generic drug companies. The company is known for its outstanding
reputation for clinical quality, developing study designs,
recruiting and screening study participants, and collecting
and reporting clinical data.
First Analysis recently participated
in a funding round that will help Bio-Kinetic nearly double
its capacity, strengthen its services in areas such as data
analytics, and add management depth required to implement
its growth plan.
The First Analysis investment team
was led by Jim Macdonald. We collaborated on this investment
with our frequent co-investor, Argentum Group. CapitalSource
Finance LLC provided debt financing.
First Analysis is a leading private
growth-equity investor. It has one of the longest records
(20 years) in private capital investing. It has invested over
$590 million, has created over $1.4 billion in fund liquidations,
and has over $180 million in active portfolio investments.
First Analysis focuses on its three sectors of expertise:
outsourced services, information technology, and chemistry-enabled
businesses.
First Analysis invests for expansion
and growth in small and mid-size companies with established
business models, high internal growth rates, and large-market
leadership potential. The firm is typically the lead or sole
investor in its portfolio companies, investing up to $10 million,
and it has a number of established co-investor relationships.
|